<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02771314</url>
  </required_header>
  <id_info>
    <org_study_id>D5160C00030</org_study_id>
    <nct_id>NCT02771314</nct_id>
  </id_info>
  <brief_title>Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC</brief_title>
  <official_title>A Longitudinal Study Evaluating Molecular Changes Associated With Resistance to First and Third (AZD9291) Generation EGFR TKIs in Patients With EGFR Mutant NSCLC Using &quot;Liquid Biopsy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the possibilities that both plasma and circulating tumor cells (CTCs) (the &quot;liquid
      biopsy&quot;) may offer, we consider that it could be feasible to longitudinally monitor the
      genetic evolution and the biologic characteristics of CTCs, by using Circulating tumor DNA
      (ctDNA) and CTCs as a source of biologic material. This approach could provide information
      regarding the genetic/molecular changes associated with primary and acquired resistance to
      AZD9291 and, thus, to facilitate to more appropriately adapt the tailored treatment in this
      particular group of NSCLC patients. It has been recently reported that the detection of
      resistant clones, based on the tumor-associated genetic aberrations in the blood, can
      identify treatment resistance up to 10 months earlier than the radiological methods
      providing, thus, the potential for an early switch to a non cross-resistant therapy in order
      to improve patients' outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer is among the most common tumor types representing 13% of the newly diagnosed
      cancers worldwide. Both the absolute and relative frequency of lung cancer has risen
      dramatically. Unfortunately, lung cancer remains by far the leading cause of cancer-related
      deaths, accounting for 18% of the total number of deaths. Non Small Lung Cancer (NSCLC)
      accounts for 85% of all cases of lung cancer and is further classified in several subtypes
      based on various molecular and histological features.

      The initial dose of 80 mg AZD9291 administered once daily orally in the fasted state can be
      reduced to 40 mg AZD9291 once daily under circumstances

      Single arm, open-label, phase II, multicenter study. NSCLC patients with activating EGFR
      mutations, who are under front line treatment with first generation EGFR TKIs according to
      the physicians' choice and present disease progression, will be treated with single agent
      AZD9291. The patients will be followed every 3 months for the detection of mutations (T790M),
      (C797S), (L858R), del 19 EGFR mutations as well as the mutations [(KRAS)/(NRAS), (BRAF),
      (PI3K)] in the serum/plasma, the determination of the serum levels of Hepatocyte Growth
      Factor (HGF), the presence of T790M (+) and C797S(+) CTCs as well as the molecular (c-MET)
      and (HER2 amplification) and phenotypic characterization of CTCs using the filtration
      platform (ISET). The elimination or the emergence of each of these circulating tumor
      biomarkers will be correlated with patients' clinical outcome [objective response to
      treatment (ORR), (PFS) and (OS)].

      There is no specific control group in this study. Biomarkers profile at baseline will be used
      as internal control for each patient to monitor changes throughout treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of resistance to first and third (AZD9291) generation EGFR TKIs, explored by studying baseline serial serum or plasma DNA specimens and baseline Circulating Tumor Cells (CTCs)</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate, assessed using RECIST 1.1</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>AZD9291</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD9291</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291</intervention_name>
    <description>AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state</description>
    <arm_group_label>AZD9291</arm_group_label>
    <other_name>Tagrisso</other_name>
    <other_name>Osimertinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years

          2. Both sexes

          3. Histologically or cytologically documented NSCLC

          4. Stage 3b (IIIb) not amenable to radical therapy or stage IV

          5. Presence of EGFR activating mutations (exon 19 deletion or L858R in exon 21)

          6. First or second line treatment with EGFR TKIs

          7. Performance status (ECOG): 0-1

          8. Measurable or evaluable disease

          9. Adequate organ function tests (Hb&gt;=10g/dL, white blood cell (WBC) &gt;=3.0 x 10^9/L,
             neutrophils count &gt;=1.5 x 10^9/L, plateletsâ‰¥100 x 10^9/L, Creatinine clearance &gt;=50
             mL/min, Total bilirubin=&lt;1.5 X UNL, aspartate aminotransferase (AST), Alanine
             Aminotransferase (ALT) and Alkaline phosphatase (ALP) =&lt;2.5 x UNL)

         10. Normal QT interval in ECG

         11. Central nervous system (CNS) metastases are allowed provided that they have been
             irradiated and the patient is clinically stable

         12. Women of child bearing potential and all men will be required to use adequate
             contraceptive measures

         13. Life expectancy of at least 3 months

         14. Written informed consent

        Exclusion Criteria:

          1. History of serious drug allergy

          2. Refractory nausea, vomiting and chronic gastrointestinal diseases

          3. Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (QTc) &gt;470 msec, obtained from 3 ECGs, using
                  the screening clinic ECG machine-derived QTc value.

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECG.

               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                  events or unexplained sudden death under 40 years of age in first-degree
                  relatives or any concomitant medication known to prolong the QT interval.

          4. Severe or uncontrolled systemic liver disease, including those with known hepatitis B,
             hepatitis C, and Human Immunodeficiency virus (HIV) infection

          5. Interstitial lung disease or pulmonary fibrosis

          6. Pregnancy, lactation or other concomitant serious medical condition

          7. Other concurrent active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athanasios Kotsakis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hellenic Oncology Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <phone>+302106448330</phone>
    <email>georgulv@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Efthimios Prinarakis, PhD</last_name>
    <phone>+302106448330</phone>
    <email>eprinarakis@horg.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Heraklion Crete</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Athanasakis</last_name>
      <phone>+302810392783</phone>
      <email>dclintrials@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Athanasios Kotsakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>251 Air Forces Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Kentepozidis, MD</last_name>
      <email>kentenik@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Nikolaos Kentepozidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anticancer Hospital of Athens &quot;Agios Savvas&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Koumakis, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Koumakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Athens Hospital &quot;Mitera&quot; Hygia Polis</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilias Athanasiadis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ilias Athanasiadis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Aretaieio&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christos Papadimitriou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christos Papadimitriou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;Evangelismos&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theodoros Tegos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Theodoros Tegos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Oncology Hospital of Athens &quot;Ag. Anargiroi&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Epaminondas Samantas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Epaminondas Samantas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IASO General Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panagiotis Katsaounis, MD</last_name>
      <phone>+302106502639</phone>
    </contact>
    <investigator>
      <last_name>Panagiotis Katsaounis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtiy Hospital of Athens &quot;Attikon&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Koumarianou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anna Koumarianou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras-Rio</name>
      <address>
        <city>Rio-Patra</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charalampos Kalofonos, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Charalampos Kalofonos, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thesaloniki &quot;G. Papanikolaou&quot;</name>
      <address>
        <city>Thesaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Konstantinos Zarogoulidis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Konstantinos Zarogoulidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabalkaniko General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christos Emmanouilidis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christos Emmanouilidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thessaloniki Bioclinic</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ioannis Boukovinas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ioannis Boukovinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>AZD9291</keyword>
  <keyword>&gt;= 2nd line</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>EGFR TKIs</keyword>
  <keyword>EGFR mutant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

